Codice QR

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations

ObjectiveTo explore the efficacy and safety of EGFR-TKI combined with thymosin therapy in advanced non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations.MethodsPatients confirmed as advanced NSCLC with active EGFR mutations were recruited from August 2008 to July 2018 retrospec...

Descrizione completa

Salvato in:
Autori principali: Yongdong Feng, Guangkuo Zhu, Song Lang, Ping Hao, Guanghui Li, Fanglin Chen, Wenlei Zhuo, Yuzhong Duan, Anmei Zhang, Zhengtang Chen, Jianguo Sun
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021-05-01
Serie:Frontiers in Oncology
Soggetti:
NSCLC
EGFR-TKI
thymosin
active EGFR mutations
efficacy
safety
Accesso online:https://www.frontiersin.org/articles/10.3389/fonc.2021.659065/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi